TianYianCha App shows that there are more than 800 patent applications on "pancreatic cancer" in China, over 180 of which have been authorized, mostly concerning pancreatic cancer detection, prevention, and treatment, including "Application of LMO7 expression level in predicting gemcitabine resistance in pancreatic cancer" "A system for pancreatic cancer detection and its reagents or kits" "Application of soluble CD58 in the prevention and treatment of pancreatic cancer" "Application of CaMKI as a therapeutic target in the preparation of pancreatic cancer therapeutic drugs" etc. Applicants of the above include hospitals, biomedical companies and so on. It is worth mentioning that the Second Hospital of Sun Yat-sen University (Sun Yat-sen Memorial Hospital of Sun Yat-sen University) has applied for several pancreatic cancer-related patents with some been authorized.

From IPRdaily

 November 13th, 2023